1. Home
  2. IMKTA vs NTLA Comparison

IMKTA vs NTLA Comparison

Compare IMKTA & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ingles Markets Incorporated

IMKTA

Ingles Markets Incorporated

HOLD

Current Price

$89.39

Market Cap

1.7B

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$16.68

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMKTA
NTLA
Founded
1963
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
1994
2016

Fundamental Metrics

Financial Performance
Metric
IMKTA
NTLA
Price
$89.39
$16.68
Analyst Decision
Buy
Analyst Count
0
23
Target Price
N/A
$20.02
AVG Volume (30 Days)
133.1K
6.4M
Earning Date
05-11-2026
05-07-2026
Dividend Yield
0.74%
N/A
EPS Growth
N/A
27.43
EPS
N/A
N/A
Revenue
$5,334,032,609.00
$67,671,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$62.75
P/E Ratio
$15.91
N/A
Revenue Growth
N/A
16.92
52 Week Low
$59.27
$7.95
52 Week High
$95.62
$28.24

Technical Indicators

Market Signals
Indicator
IMKTA
NTLA
Relative Strength Index (RSI) 50.23 64.05
Support Level $86.11 $11.73
Resistance Level $89.76 $26.99
Average True Range (ATR) 2.34 1.18
MACD -0.18 0.28
Stochastic Oscillator 39.47 87.18

Price Performance

Historical Comparison
IMKTA
NTLA

About IMKTA Ingles Markets Incorporated

Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: